- Today
- Holidays
- Birthdays
- Reminders
- Cities
- Atlanta
- Austin
- Baltimore
- Berwyn
- Beverly Hills
- Birmingham
- Boston
- Brooklyn
- Buffalo
- Charlotte
- Chicago
- Cincinnati
- Cleveland
- Columbus
- Dallas
- Denver
- Detroit
- Fort Worth
- Houston
- Indianapolis
- Knoxville
- Las Vegas
- Los Angeles
- Louisville
- Madison
- Memphis
- Miami
- Milwaukee
- Minneapolis
- Nashville
- New Orleans
- New York
- Omaha
- Orlando
- Philadelphia
- Phoenix
- Pittsburgh
- Portland
- Raleigh
- Richmond
- Rutherford
- Sacramento
- Salt Lake City
- San Antonio
- San Diego
- San Francisco
- San Jose
- Seattle
- Tampa
- Tucson
- Washington
Brisbane Today
By the People, for the People
Vera Therapeutics Announces Inducement Grants
Biotech firm grants stock options and RSUs to 89 new employees under Nasdaq listing rule
Apr. 13, 2026 at 4:41am
Got story updates? Submit your updates here. ›
Vera Therapeutics' latest round of inducement grants to new hires reflects the biotech's commitment to building a world-class team to advance its immunology-focused drug pipeline.Brisbane TodayVera Therapeutics, a late-stage biotech company focused on serious immunological diseases, announced that it has granted inducement awards consisting of stock options and restricted stock units (RSUs) to 89 new employees under the company's 2024 Inducement Plan. The awards were approved by Vera's Compensation Committee as an inducement material to the new employees' employment in accordance with Nasdaq Listing Rule 5635(c)(4).
Why it matters
Inducement grants like these are common practice for public companies to attract and retain top talent, especially in competitive fields like biotech. The grants align the new employees' interests with those of Vera's shareholders by tying a portion of their compensation to the company's stock performance over time.
The details
The inducement awards include 258,200 non-qualified stock options with an exercise price of $40.33 per share, and 131,925 RSUs. The stock options will vest over 4 years, with 25% vesting on the first anniversary and the remaining 75% vesting monthly over the following 36 months. The RSUs will also vest over 4 years, with 25% vesting on each anniversary of May 20, 2026. All awards are subject to the new employees' continued service with Vera.
- The Compensation Committee approved the inducement grants on April 8, 2026.
- The stock options have an exercise price based on Vera's closing trading price on April 8, 2026.
The players
Vera Therapeutics, Inc.
A late clinical-stage biotechnology company focused on developing treatments for serious immunological diseases.
Compensation Committee
The committee of Vera's Board of Directors that approved the inducement grants.
What’s next
The new employees will begin vesting their stock options and RSUs according to the schedules outlined, provided they maintain their continued service relationship with Vera Therapeutics.
The takeaway
Vera Therapeutics is using standard biotech industry practices to incentivize and retain new talent as it advances its pipeline of immunology-focused drug candidates. These types of inducement grants help public companies like Vera attract top scientific and business expertise to drive their long-term growth and success.
